JEFFREY M. DAYNO, M.D.
President and Chief Executive Officer
Jeffrey M. Dayno, M.D., is President and Chief Executive Officer of Harmony Biosciences. A nationally recognized expert in neuroscience and leader at Harmony Biosciences since the company's inception, Dr. Dayno is responsible for overseeing the company's business growth including Harmony’s successful acquisitions of Zynerba Pharmaceuticals in 2023 and Epygenix Therapeutics, Inc. in 2024, advancement of Harmony's clinical development programs, and buildout of the company's pipeline. He has been the driving force behind Harmony's patient-focused drug development model, which uses patient insights to inform clinical research programs and building a pipeline focused on potential, next-generation, innovative treatments to help people living with rare neurological diseases and unmet medical needs.
Dr. Dayno is a neurologist with 10 years of experience in clinical and academic medicine followed by over 25 years of experience in the pharmaceutical industry, touching every aspect of the business. He has held leadership roles at Merck & Co., Cephalon, and ViroPharma, building and leading clinical, regulatory, and medical affairs teams toward multiple NDA approvals and medical support for successful product launches. He also served as Principal Investigator on numerous clinical trials and has published and lectured extensively on various topics around evolving pharma business models, value creation and impact, as well as on numerous topics within the field of neurology. In 2023, Dr. Dayno was named to the PharmaVoice 100 list and in 2024 he received the Frank Baldino Bioscience CEO of the Year Award from Life Sciences Pennsylvania, which recognizes visionary leadership and active participation to advance the life sciences industry.
Dr. Dayno earned his medical degree from Temple University School of Medicine, completed his residency training in Neurology at Temple University Hospital, and completed a fellowship in Stroke and Cerebrovascular Disorders in the Department of Neurology at Henry Ford Hospital, which held a National Institutes of Health program grant in stroke research. He is on the Board of Emalex Biosciences, is a member of the Board of Life Sciences Pennsylvania (LSPA), serves on the Board of Advisors for Life Science Cares Philadelphia, and is a member of the Board of Visitors of the Lewis Katz School of Medicine at Temple University. Dr. Dayno has served as the Industry Representative for FDA's Peripheral and Central Nervous System Drugs Advisory Committee, as well as served as an expert on several FDA industry advisory panels.